What is the recommended medication management for influenza?

Medication Management for Influenza

Antiviral Treatment

Oseltamivir 75 mg orally twice daily for 5 days is the first-line antiviral treatment for influenza in adults and adolescents, initiated ideally within 48 hours of symptom onset. 1, 2

Indications for Antiviral Therapy

Antiviral treatment should be offered to patients who meet ALL of the following criteria: 1

• Acute influenza-like illness
• Fever >38°C in adults (>38.5°C in children)
• Symptomatic for ≤48 hours

Priority Populations for Treatment

Regardless of timing or vaccination status, initiate antivirals immediately for: 1

• Any hospitalized patient with suspected or confirmed influenza
• Patients with severe, complicated, or progressive illness
• Children or adults at high risk of complications (chronic cardiac/respiratory disease, immunocompromised, elderly, pregnant women)

Dosing by Age and Weight

Adults and adolescents ≥13 years: Oseltamivir 75 mg orally twice daily for 5 days 1, 2

Pediatric patients (≥1 year to 12 years): 2

• ≤15 kg: 30 mg twice daily
• 15.1-23 kg: 45 mg twice daily
• 23.1-40 kg: 60 mg twice daily

• 40 kg: 75 mg twice daily

Infants (2 weeks to <1 year): 3 mg/kg twice daily for 5 days 2

Important Exceptions to the 48-Hour Rule

Severely ill hospitalized patients, particularly if immunocompromised, may benefit from antiviral treatment started >48 hours from symptom onset, though evidence is limited. 1

Immunocompromised or very elderly patients unable to mount adequate febrile response may still be eligible for treatment despite lack of documented fever. 1

Alternative Antiviral Options

Baloxavir marboxil is an alternative single-dose oral antiviral: 3

• 40-<80 kg: 40 mg single dose
• ≥80 kg: 80 mg single dose
• Must be taken within 48 hours of symptom onset
• Avoid coadministration with dairy products, calcium-fortified beverages, or polyvalent cation-containing products

Zanamivir (inhaled) is an alternative for patients without chronic respiratory disease, though more difficult to administer 1

Expected Benefits of Antiviral Treatment

Antiviral therapy provides: 1, 4

• Reduction in illness duration by approximately 24 hours
• Possible reduction in hospitalization rates
• Decreased use of subsequent antibiotics
• Faster return to normal activity levels

Note: Current evidence does not definitively demonstrate mortality reduction, though it does not rule it out. 1

Common Adverse Effects

Nausea occurs in approximately 10% of oseltamivir recipients and can be minimized by taking the medication with food. 1, 4

---

Antibiotic Management

Uncomplicated Influenza Without Pneumonia

Previously well adults with acute bronchitis complicating influenza do NOT routinely require antibiotics in the absence of pneumonia. 1

Consider antibiotics in previously well adults who develop: 1

• Recrudescent fever (fever returning after initial improvement)
• Increasing dyspnea
• Worsening symptoms after 2 days

Patients at high risk of complications should be strongly considered for antibiotics when lower respiratory tract features are present, even without confirmed pneumonia. 1, 5

Preferred oral regimens: 1

• Co-amoxiclav (amoxicillin-clavulanate) 625 mg three times daily
• Doxycycline 200 mg loading dose, then 100 mg once daily

Alternative regimens (penicillin allergy): 1

• Clarithromycin 500 mg twice daily
• Erythromycin 500 mg four times daily
• Respiratory fluoroquinolone (levofloxacin or moxifloxacin) with activity against S. pneumoniae and S. aureus

Non-Severe Influenza-Related Pneumonia

All patients with influenza-related pneumonia require antibiotics, initiated within 4 hours of hospital admission. 1, 5

Preferred oral regimens: 1, 5

• Co-amoxiclav 625 mg three times daily
• Doxycycline 200 mg loading, then 100 mg once daily

Parenteral options (when oral contraindicated): 1, 5

• IV co-amoxiclav
• Cefuroxime (2nd generation cephalosporin)
• Cefotaxime (3rd generation cephalosporin)

Duration: 7 days for uncomplicated pneumonia 1, 5

Severe Influenza-Related Pneumonia

Immediate parenteral combination antibiotic therapy is required upon diagnosis. 1, 5

Preferred combination regimen: 1, 5

• IV co-amoxiclav OR cefuroxime OR cefotaxime
• PLUS IV clarithromycin OR erythromycin

Alternative combination: 1

• IV levofloxacin (respiratory fluoroquinolone with enhanced pneumococcal activity)
• PLUS broad-spectrum beta-lactamase stable antibiotic OR macrolide

Duration: 1, 5

• 10 days for severe, microbiologically undefined pneumonia
• Extend to 14-21 days if S. aureus or gram-negative enteric bacilli suspected or confirmed

Transition to Oral Therapy

Switch from IV to oral antibiotics when: 1, 5

• Clinical improvement occurs
• Temperature normal for 24 hours
• No contraindication to oral route exists

Treatment Failure

For non-severe pneumonia failing combination therapy: Switch to fluoroquinolone with effective pneumococcal and staphylococcal coverage 1, 5

For severe pneumonia not responding to combination therapy: Add antibiotics effective against MRSA (vancomycin or linezolid) 1, 5

---

Critical Pitfalls to Avoid

Never delay antiviral treatment while awaiting laboratory confirmation—clinical diagnosis is sufficient, and early treatment (within 24 hours) provides maximum benefit. 1, 6, 7

Do not use amantadine or rimantadine—high resistance rates make these agents ineffective for current influenza strains. 1, 8

Avoid aspirin in children with influenza due to risk of Reye syndrome. 1

Remember that influenza-related pneumonia requires coverage for S. aureus in addition to typical community-acquired pneumonia pathogens—this distinguishes it from standard CAP treatment. 1, 5

Do not assume antibiotics are needed for all influenza cases—uncomplicated influenza in previously healthy individuals does not require antibiotics unless secondary bacterial infection develops. 1